Why this peptide is on people's radar
Ara-290's story starts with an observation about EPO. Erythropoietin's classic role is stimulating red blood cell production, that's why it's used in chronic kidney disease anemia and (controversially) by endurance athletes. But in the early 2000s, researchers noticed that EPO also has tissue-protective effects in the brain, kidney, heart, and peripheral nerves. The protective effects appeared to work through a different receptor than the one driving red cell production, what later came to be called the "innate repair receptor" or IRR.
Anthony Cerami's group at Araim Pharmaceuticals figured out which part of the EPO molecule was responsible for the tissue-protective activity. Ara-290 is an 11-amino-acid fragment of that region (helix B of EPO), engineered to activate the protective receptor without binding the classical EPO receptor. The design accomplishes something hard in pharmacology: separating two effects of the same parent molecule, keeping the desired one and dropping the undesired one. In Ara-290's case, the "undesired" effect is the cardiovascular risk that comes with raising hematocrit, a real problem with classical EPO.
Phase 2 trials in diabetic peripheral neuropathy reported improvements in measures of small nerve fiber density and reductions in neuropathic pain over weeks of dosing. A separate Phase 2 in sarcoidosis-related small fiber neuropathy reported similar signals. The trial program has been smaller than the more-famous metabolic peptides on this site, but the mechanistic story is unusually clean.
What people are usually trying to do with it
People reading about Ara-290 are usually focused on:
- Diabetic peripheral neuropathy, pain and small-fiber damage in long-standing diabetes
- Small-fiber neuropathy from other causes (sarcoidosis, idiopathic, post-COVID)
- Tissue protection in chronic-injury contexts
- An EPO-related option that doesn't carry erythropoiesis risk
- Anti-inflammatory / nerve-repair support in chronic disease
What the science actually shows
Plain-English summary:
Selective IRR activation, not EPO receptor
Pharmacological characterization confirms Ara-290 binds the heteromeric tissue-protective receptor (EPOR/βcR) without significantly activating the homodimeric EPO receptor that drives erythropoiesis.
Diabetic neuropathy Phase 2
Phase 2 trial in adults with diabetic peripheral neuropathy reported improvements in intraepidermal nerve fiber density and reductions in neuropathic pain over 28 days of subcutaneous dosing.
Sarcoidosis-related small fiber neuropathy
Studies in sarcoidosis patients with small fiber neuropathy reported improvements in autonomic and pain symptoms.
Anti-inflammatory and tissue-protective biology (preclinical)
Animal studies report tissue-protective effects in models of ischemic injury, kidney damage, and inflammatory conditions, consistent with the IRR-mediated effects of full EPO without the hematopoietic effects.
What hasn't been demonstrated
FDA approval. Phase 3 confirmation. Long-term safety data. Real-world translation in broader patient populations. Clinical effects on chronic conditions outside the specific neuropathy trials.
The honest read
What's solid:
The pharmacological design, separating tissue protection from erythropoiesis, is a real piece of clever drug engineering. Phase 2 trial signals in diabetic neuropathy and sarcoidosis-related neuropathy are encouraging. The mechanism is well-characterized.
What's still being worked out:
Phase 3 confirmation hasn't happened yet. The clinical-development program has moved more slowly than larger pharmaceutical programs. Whether Ara-290 reaches FDA approval depends on additional trial results that aren't yet public.
What's hyped beyond the evidence:
Treating Ara-290 as a general anti-inflammatory or "tissue repair" peptide for broad use. The clinical data is in specific neuropathy populations. The broader applications discussed in research-peptide channels (general inflammation, fatigue, recovery) rest on extrapolation from the neuropathy data.
Things to know if you're looking into it
- Investigational status: Phase 2 trials have completed in defined indications. Not FDA-approved. No Phase 3 trials currently registered.
- Different from EPO: doesn't raise red blood cell count. The whole pharmacological point is to separate tissue protection from erythropoiesis.
- How it's used in research: typically a small subcutaneous injection daily over weeks. Trial protocols have used 4 mg daily for 28 days in diabetic neuropathy.
- Regulatory status: not FDA-approved. Not on the FDA Category 2 list as of 2026.
- Healthcare provider involvement: appropriate, especially for anyone with peripheral neuropathy serious enough to consider experimental peptides.
- Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.
What people often ask
Is Ara-290 the same as EPO?
No. Ara-290 is an 11-amino-acid fragment of a specific region of EPO, engineered to activate only the tissue-protective receptor without driving red blood cell production. EPO is the full glycoprotein hormone with both effects.
Does it help with diabetic neuropathy?
Phase 2 trial signals are encouraging, improvements in nerve fiber density and pain over 28 days of dosing. Phase 3 confirmation hasn't happened. Anyone with diabetic neuropathy should be working with their endocrinology / neurology team.
Will it raise my hematocrit?
No, that's the whole pharmacological point. The molecule was specifically designed to activate the tissue-protective EPO receptor pathway without activating the classical EPO receptor that drives erythropoiesis.
Is it FDA-approved?
No. Currently in clinical-development status with Phase 2 trial data published. Not FDA-approved.
How is it administered?
Subcutaneous injection, daily, in trial protocols. Typical Phase 2 dose was 4 mg daily for 28-day cycles.
Can it help with chronic pain or fibromyalgia?
The clinical data is in specific neuropathy populations. Whether Ara-290 helps broader chronic-pain conditions hasn't been studied. Anyone with chronic pain should be working with appropriate specialists.
FDA and regulatory status
Status as of May 5, 2026: Not FDA-approved for any medical indication. Phase 2 clinical trials completed in diabetic neuropathy and sarcoidosis-related small fiber neuropathy. No active Phase 3 trials registered as of this date. Not currently on the FDA Category 2 list. Status updates land here when they happen.
Want to go deeper?
Mechanism, the IRR receptor, dosing, and references.
Background
Ara-290 (cibinetide, pyroglutamate helix B surface peptide / pHBSP) is an 11-amino-acid synthetic peptide derived from helix B of erythropoietin. Developed by Araim Pharmaceuticals (Anthony Cerami's group). Pyroglutamate-modified at the N-terminus for stability.
Mechanism of action
Innate Repair Receptor (IRR) activation
Ara-290 binds a heteromeric receptor complex composed of the EPO receptor (EPOR) and the common β-receptor (βcR), distinct from the EPOR homodimer that drives erythropoiesis. Activation of the IRR triggers anti-apoptotic, anti-inflammatory, and tissue-protective signaling pathways.
No effect on red cell production
Because Ara-290 doesn't bind the EPOR homodimer, it doesn't drive erythropoiesis. This separation is the defining pharmacological feature.
References
- Brines M, Patel NS, Villa P, et al. (2008). "Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin." Proc Natl Acad Sci USA, 105(31), 10925–10930. PubMed
- Brines M, Dunne AN, van Velzen M, et al. (2014). "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes." Mol Med, 20, 658–666. PubMed
- Heij L, Niesters M, Swartjes M, et al. (2012). "Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study." Mol Med, 18(1), 1430–1436. PubMed
- Brines M, Cerami A. (2008). "Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response." J Intern Med, 264(5), 405–432. PubMed